Skip to main content
Premium Trial:

Request an Annual Quote

Compugen Reports Revenue Slide, Stagnant R&D, Narrowed Net Loss in Q3

NEW YORK, Oct. 24 - Compugen today said that a decrease in third-quarter revenue and stagnant R&D spending helped narrow net loss.

 

Revenue for the period ended Sept. 30 was $2.8 million, down from $3.1 million reported one year ago, Compugen said. Products and services accounted for $2.4 million of that (a decrease from the third quarter 2001), while income from R&D grants comprised around $460,000 (an increase over the same period last year).

 

R&D spending was virtually unchanged at $3.5 million, the company said. Still, net loss for the third quarter narrowed to $3.8 million, or $.11 per share, from $4.4 million, or $.14 per share, from the third quarter 2001.

 

Compugen said it had roughly $59 million in cash, cash equivalents, and short-term investments as of Sept. 30. It had $33.3 million in cash, cash equivalents, and short-term investments as of June 30.

 

Click here for more information.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more